Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Urologie
Erschienen in: Der Urologe 9/2009

01.09.2009 | Leitthema

Uro-Onkologie – Update 2009

verfasst von: Prof. Dr. T. Otto

Erschienen in: Die Urologie | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Auszug

Die Aktualität des vorliegenden Beitrages stützt sich auf die für das Gebiet der Uroonkologie führenden Weltkongressen des Jahres 2009:
1.
European Association of Urology 17. bis 21. März 2009, Stockholm,Schweden,
 
2.
American Urological Association 25. bis 30. April 2009, Chicago, USA,
 
3.
American Association of Clinical Oncology 29. Mai bis 2. Juni 2009, Orlando, USA.
 
…
Literatur
1.
ABC (3003) Who will take responsibility forcorporate killing? Lancet 361:1921–1927
2.
Abdi H, Dalla Pria M, De Bei E et al (2007) Randomized clinical trial of bowel preparation versus no preparation before ileal urinary diversion. Eur Urol 6(2): 291
3.
Aboseif SR, Borirakchanyavat S, Lue TF et al (1998) Continence mechanism of the ilealneobladder in women: A urodynamics study. World J Urol 16: 400–404PubMed
4.
Abratt RP, Brune D, Dimopoulos M-A et al (2005) Randomised phase III study of intravenousvinorelbine plus hormone therapy versus hormone therapy alone in hormonerefractory. Ann Oncol 15(11):1613–1621
5.
Ahlgren G et al (2008) Nerve sparing radical prostatectomy results. Eur Urol 7(3):681
6.
Akaza H et al (2007) Uncontrolled confirmatory trial of single agent sorafenib in japanese patients with advanced renal cell carcinoma. Eur Urol 6(2):859
7.
Albers P et al (2008) Randomised phase III trial comparing RPLND with one course of adjuvant PEB chemotherapy in patients with stage I NSGT-updated results of AUO trial 01/94. Eur Urol 7(3):54
8.
Albers P et al (2008) Randomized phase III trial of 2nd line Gemcitabine/Paclitaxel chemotherapy in patients with advanced bladder cancer: temporary versus maintenance treatment (AUO trial AB 20/99). J Clin Oncol 26:5030
9.
Andriole GL et al (2009) Mortality results from a randomized prostate cancer screening trial. NEJM 360(13):1310–1319PubMed
10.
Aron M et al(2008) Laparoscopic renal cryablation. J Urol 179(4):596
11.
Arora A et al (2009) Final outcome of patients with prostate cancer suitable for active surveillance but treated surgically. Eur Urol 8(4):960
12.
Atala A et al. (2006) Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 367:1241–1246PubMed
13.
Atkins MB et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5): 909–918PubMed
14.
Attard G et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration resistant prostate cancer commonly remains hormone driven. m JCO 26:4563
15.
Atzpodien J et al (2006) Interleukin-2/interferonalpha2a/13-retinoic acid-based chemoimmunotherapyin advanced renal cell carcinoma: resultsof a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 95:463–469PubMed
16.
Autorino R et al (2008) What happens to the abstracts presented at the SIU meeting? Urology 71: 367–371PubMed
17.
Bajetta E et al (2008) Efficacy and safety of first line Bevacizumab plus IFN in patients>65 years with mRCC. J Clin Oncol 26:5095
18.
Bajorin DF et al (2006) Phase III trial of conventional-dose chemotherapy alone or with high dose chemotherapy for metastatic germ cell tumor patients. ASCO 24(18 Suppl):4510
19.
Ball S et al (2009) Sacrifice of sartorius in inguinal lymphadenectomy: Does it increase morbidity? Eur Urol 8(4):998
20.
Barbieri CE et al (2007) Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol 177(4):1513
21.
Barnett S et al (2009) Use of 5 alpha reductase inhibitors for prostate cancer chemoprevention: ASCO/AUA 2008 clinical practice guideline. J Urol 181:1642–1657
22.
Bastien L et al (2009) Biomarkers of sunitinib clinical response in metastatic renal clear cell carcinoma. Eur Urol 8(4):710
23.
Baxter NN, Tepper JE, Durham SB et al (2005) In-creased risk of rectal cancer after prostate radia- tion: a population based study. Gastroenterology 128(4):819–824PubMed
24.
Beck J et al (2008) A large open label non comparative phase III study of sorafenib in european patients with advanced renal cell carcinoma. Eur Urol 7(3):694
25.
Beemster P et al (2007) Laparoscopic cryosurgery of small renal tumours. Eur Urol 6(2):843
26.
Beer TM et al (2009) Phase II study of first line sagopilone combined with prednisone in patients with metastatic castration resistant prostate cancer. JCO 27(15 Suppl):5059
27.
Bellmunt J et al (2008) Randomized phase III trial of Vinflunine plus best supportive care versus best supportive care alone as 2nd line therapy after a platinum containing regimen in advanced TCC. J Clin Oncol 26:5028
28.
Bellmunt J et al (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology, 2008
29.
Benway BM et al (2009) Robotic partial nephrectomy versus laparoscopic partial nephrectomy: comparison of operative data and clinical outcome. Eur Urol 8(4):810
30.
Beyer J et al (2009) High dose chemotherapy as second salvage treatment in patients with multiple relapsed or refractory germ cell tumors. JCO 27(Suppl 15):5082
31.
Bhargava P et al (2009) Updated activity and safety results of a phase II randomized discontinuation trial of AV-951, a potent and selective VEGFR1, 2, 3 kinase inhibitor in patients with renal cell carcinoma. JCO 27(Suppl 15):5032
32.
Bhatt A et al (2006) Neurovascular preservation in orthotopic cystectomy: impact on female sexual function. Urology 67:742–745PubMed
33.
Bhoopalam N et al (2008) A phase III trial of zoledronic acid to prevent osteoporosis in men on early versus prolonged androgen deprivationtherapy in a high risk population. J Urol 179(4):720
34.
Biers S et al (2007) Outpatient electromotive drug administration of local anaesthesia for biopsy and cystodiathermy of recurrent low grade bladder tumors. Eur Urol 6(2): 599
35.
Bill-Axelson A et al. (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the scandinavian prostate cancer group 4 randomized trial. JnatlCancerInst 100:1144–1154
36.
Blana A et al (2007) Long term results with HIFU in 140 patients with localized prostate cancer. Eur Urol 6(2): 708
37.
Bliuc D et al (2009) Mortality risk associated with low trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521PubMed
38.
Bloom JH et al (1999) Radical nephrectomy with and without lymph node dissection. Eur Urol 36 (6): 570–575
39.
Boccon-Gibod L et al (2008) Degarelix compared to leuprolide in a 12 months randomized open label parallel group phase III study in prostate cancer patients Eur Urol 537
40.
Bohjani N et al (2008) External beam radiation therapy increases the rate of secondary malignancies relative to radical prostatectomy in men with prostate cancer. J Urol 179(4):318
41.
Böhle A et al (2009) Single postoperative instillation of gemcitabine in patients with superficial transitional cell carcinoma of the bladder: a randomized double-blind, placebo controlled phase III multicenter study. J Urol 181(4):1908
42.
Bolla M et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578PubMed
43.
Bolla M et al (2008) Six month concomitant and adjuvant hormonal treatment with external beam irradiation is inferior to 3-years hormonal treatment for locally advanced prostate cancer: results of the EORTC randomised phase III trial 22961. Eur Urol 7(3):186
44.
Borchers H et al (2005) Europ Urol 4(Suppl 3):249
45.
Bracarda S et al (2008) Sorafenib plus Interferon in metastatic renal cell carcinoma. Eur Urol 7(3):696
46.
Bracarda S et al (2009) Sunitinib in metastatic renal cell carcinoma patients with brain metastases: Data from an expanded access study. Eur Urol 8(4):247
47.
Brausi M et al (2007) Percutaneous radiofrequency ablation vs watchful waiting for small renal tumors: First results of a prospective study. Eur Urol 6(2):842
48.
Briganti A et al (2009) Adjuvant radiotherapy has no impact on biochemical recurrence free survival in prostate cancer patients with seminal vesicles invasion treated with radical prostatectomy. Eur Urol 8(4):752
49.
Brinkmann B (1997) Errors in autopsy in Germany. Arch Kriminol 199(3-4):65–74
50.
Brunken C et al (2007) Bipolar transurethral resection of bladder cancer: results after resection of the ureteral orifice. Eur Urol 6(2): 604
51.
Bukowski R et al (2007) Safety analysis of the advanced renal cell carcinoma Sorafenib (ARCCS) study, an expanded access program. Eur Urol 6(2):858
52.
Bukowski R (2007) Novel agents in renal cell carcinoma. The second european international kidney cancer symposium, Rom 5.5.2007
53.
Bukowski R et al (2008) Sorafenib in advanced renal cell carcinoma: survival and biomarker results from a phase III trial. Eur Urol 7(3):695
54.
Bukowski RM et al (2008) Safety and efficacy of sorafenib in elderly patients: J Clin Oncol 26:5045
55.
Calais Da Siva F et al (2005) J Urol 173(4)
56.
Calais Da Siva F et al (2006) Eur Urol 5(Suppl 2):1066
57.
Calais Da Siva FE et al (2007) Phase III study of intermittent monotherapy versus continuous combined androgen deprivation. Eur Urol 6(2): 22
58.
Calais Da Silva F et al (2008) Evaluation of qualità of life, side effects and duration of therapy in a phase III study of intermittent monotherapy versus continuous combined androgen deprivation. J Urol 179(4):719
59.
Calais Da Silva F et al (2009) Phase III study of intermittent monotherapy vs continuous combined androgen deprivation. J Urol 181(4):646
60.
Calleary J et al (2007) HIFU for localized prostate cancer. Eur Urol 6(2): 705
61.
Camera C et al (2008) High prevalence of metabolic syndrome in patients under long term hormonal therapy for prostate cancer. Preliminary report. J Urol 179(4):401
62.
Campos RSM et al. (2006) E-cadherin, MMP-9 as prognostic markers in penile cancer: analysis of 125 patients. Urology 67:797–802PubMed
63.
Capitanio U et al (2009) The use of LHRH agonists administered to patients with prostae cancer predisposes to dementia: a population based analysis. J Urol 181(4):828
64.
Carlsson S et al (2007) Learning curve concerning positive surgical margins for da vinci robotic assisted laparoscopic radical prostatectomy. Eur Urol 6(2): 409
65.
Castillo O et al (2007) Primari laparoscopic RLA for clinical stage I NSGT. J Urol 177(4):1003
66.
Cella D et al (2007) Effects of Sunitinib versus interferon alfa in health related quality of life in patients with metastatic renal cell carcinoma: Results from a randomised multinational phase III trial. Eur Urol 6(2):861
67.
Cestari A et al (2007) Laparoscopic renal cryoablation of small renal masses. Eur Urol 6(2):665
68.
Chamie K et al (2007) Cystectomy in the elderly. J Urol 177(4):1516
69.
Chamie K et al (2008) Agent orange exposure, vietnam war veterans and the risk of prostate cancer. J Urol 179(4):421
70.
Chamie K et al (2008) Increased risk of secondary malignancy in patients on active surveillance for NSGCT. J Urol 179(4):492
71.
Chamie K et al (2008) The impact of secondary malignancies on survival in patients treated with external beam radiation therapy for prostate cancer. J Urol 179(4):393
72.
Chawla SN et al (2005) Observation of enhancing renal masses: a metaanalysis of worldwide data. J Urol 173(4)
73.
Chi KN et al (2009) Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer. JCO 27(Suppl 15):5012
74.
Chin JL et al (2006) J Urol 175(4):1130
75.
76.
Cohen MS et al (2007) A meta-analysis evaluating the accuracy of prostate Gleason biopsy in over 110000 patients. J Urol 177(4):743
77.
Coleman MP et al (2008) Cancer survival in five continents: A world wide population based study CONCORD. Lancet Oncology 9:730–756PubMed
78.
Collette L et al (2009) Health related quality of life and symptoms in an international phase III trial of long term vs short term androgen suppression and radiation therapy for locally advanced prostate cancer. Eur Urol 8(4):745
79.
Colli JL et al (2008) Renal cell carcinoma incidence and mortality rates compared to risk factors in the United States. J Urol 179(4):486
80.
Concato J et al (2006) Ann Intern Med 166:38–43
81.
Conort P et al (2008) Treatment of localized prostate cancer by high intensity focused ultrasound ; results of the first french prospective trial on patients not previously treated: minimum of five years follow up. J Urol 179(4):1452
82.
Culp SH et al (2009) Identifying patients with metastatic renal cell carcinoma who will not benefit from cytoreductive neprectomy. J Urol 181(4):1394
83.
Daneshmand S et al (2008) Predictive role of FDG PET in advanced seminoma following chemotherapy. J Urol 179(4):773
84.
Danila DC et al (2009) Phase II multicenter study of abiraterone plus prednisone therapy in docetaxel treated castration resistant prostate cancer. JCO 27:15 (Suppl):5048
85.
Demkow T et al (2008) A multicentric phase II randomised study of oral vinorelbine plus hydrocortisone and intravenous vinorelbine plus hydrocortisone as first line chemotherapy of metastatic androgen independent prostate cancer. Eur Urol 7(3):639
86.
87.
Depuy V et al (2006) Eur Urol Suppl 5(2):142
88.
Deras IL et al (2009) PCA3 molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (in press)
89.
Derksen JE et al (2005) J Urol 173(4)
90.
Dhar N et al (2006) J Urol 175(4):146
91.
Di Stasi SM et al (2005) J Urol 173(4)
92.
Di Stasi SM et al (2006) J Urol 175(4):830
93.
Di Stasi SM et al (2008) Sequential BCG and electromotive Mitomycin-C versus BCG alone for high risk superficial bladder cancer: Long term follow up results of a prospective controlled study. J Urol 179(4):1707
94.
Djavan B et al (2006) Eur Urol Suppl 5(2):427
95.
Djavan B et al (2008) Radical prostatectomy versus radiation therapy in men with T3 prostate cancer: 10 years follow up. Eur Urol 7(3):130
96.
Doehn C et al (2004) Eur Urol 3(Suppl 2):429
97.
Doehn C et al (2006) Eur Urol Suppl 5(2):1054
98.
Doehn C et al. An adjuvant vaccination with reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy. J Urol 177(4):500, 2007
99.
Dreicer R et al (2008) Phase II trial of Sorafenib in advanced carcinoma of the urothelium: a trial of the ECOG. J Clin Oncol 26:5083
100.
Duclos M et al (2008) Hypofractionated external beam radiation therapy and single fraction HDR brachytherapy: improving the results in the treatment of intermediate risk prostate cancer. J Urol 179(4):1156
101.
Dutcher J et al (2008) Sequential axitinib therapy of patients with refractory mRCC. J Clin Oncol 26:5127
102.
Ecke TH et al (2006) Oncol Rep 16(6):1381–138
103.
Eden CG et al (2008) The UK‚s first 1000 cases of laparoscopic radical prostatectomy. Eur Urol 7(3):383
104.
Eisen T et al (2006) ASCO 24(18 Suppl):4524
105.
Eisen T et al (2007) Randomized phase III trial in Sorafenib in advanced renal cell carcinoma: Impact of crossover on survival. Eur Urol 6(2):857
106.
Eisen T et al (2009) Phase II study of BAY 73–4506, a multikinase inhibitor in prviously untreated patients with metastaic or unresectable renal cell cancer. JCO 27(Suppl 15):5033
107.
El-Mekresh M et al (2007) Survival predictors among 2730 cases of radical cystectomy. Eur Urol 6(2): 12
108.
Eri LM et al (2007) Laparoscopic radical prostatectomy, our first four years. Eur Urol 6(2): 925
109.
Escudier BJ et al (2006) Eur Urol Suppl 5(2):1058
110.
Escudier BJ et al (2007) Bevacizumab plus Interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised double blind phase III trial. Lancet 370:2103–2111PubMed
111.
Escudier BJ et al (2007) Sorafenib in advanced clear cell renal cell carcinoma. NEJM 356(2):125–134PubMed
112.
Escudier BJ et al (2008) Targeted therapies in the mangement of renal cell carcinoma: the role of bevacizumab. Biologics: Targets & Therapy 2(3):517–530
113.
Escudier BJ et al (2008) Update on AVOREN trial in metastatic renal cell carcinoma. J Clin Oncol 26:5025
114.
Escudier BJ et al (2009) Final results of the phase III randomized double blind AVOREN trial of first line bevacizumab + interferon alpha 2a in metastatic renal cell carcinoma. JCO 27(Suppl 15):5020
115.
Faivre S et al (2006) Nature Rev (5):671–668
116.
Falkensammer CE et al (2008) Dendritic cell vaccination of metastatic renal cell carcinoma patients. J Urol 179(4):488
117.
Feil G et al (2008) Urine based tumor marker tests are a helpful tool in early diagnosis of bladder cancer in high risk populations-interim data of the prospective study uroscreen. J Urol 179(4):945
118.
Feldman DR et al (2008) Phase I trial of bevacizumab plus sunitinib in patients with mRCC. J Clin Oncol 26:5100
119.
Feldman DR et al (2009) Paclitaxel plus ifosfamide followed by high dose carboplatin and etoposide with autologous stem cell support for patients with previously treated germ cell tumors. JCO 27 (Suppl 15):5027
120.
Ficarra V et al (2009) Retropubic, laparoscopic and robotic assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 55:1037–1063PubMed
121.
Figg WD et al (2008) Randomized phase III trial of thalidomide or placebo for non metastatic PSA recurrent prostate cancer treated with intermittent therapy. J Clin Oncol 26:5016
122.
Figg WD et al (2009) A double blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol 181:1104–1113PubMed
123.
Figlin RA et al (2008) Overall survival with sunitinib versus interferon as first line treatment of metastatic RCC. Clin Oncol 26:5024
124.
Flanigan R. C et al (2001) Engl J Med 345 (23): 1655–1659
125.
Fossa SD et al (2000) Eur Urol 37(5): 541–51
126.
Frank SJ et al (2008) Prostate brachytherapy-the M. D. Anderson Cancer Center experience. J Urol 179(4):1153
127.
Freedland SJ, Partin AW (2009) Vitamins E and C in the prevention of prostate cancer and total cancer in men. The physicians health study II randomized controlled trial. JAMA 302(1):52–62
128.
Gallagher DJ et al (2008) Final results of a phase II study of sunitinib in patients with relapsed or refractory urothelial cancer. J Clin Oncol 26:5082
129.
Galsky MD et al (2006) ASCO 24(18 Suppl):4524
130.
Garcia Rojo D et al (2009) Total fluid and water consumption and the joint effect to disinfection by-products on risk of bladder cancer. Eur Urol 8(4):669
131.
Garcia-Closas M et al (2005) Lancet 366:649–659
132.
Garcia-Rojo D et al (2008) p53 in bladder cancer prognosis. Results from a prospective multicenter study in spain. J Urol 179(4):1708
133.
Garcia-Rojo D et al (2008) Risk of bladder cancer associated with family history of cancer: Do low penetrance polymorphism account for the increased risk? J Urol 179(4):936
134.
Gatti R et al (1998) Acta Anatomica 163: 179–183
135.
George DJ et al (2008) Sunitinib in combination with Docetaxel and prednisone in patients with metastatic hormone refractory prostate cancer. J Clin Oncol 26:5131
136.
Gerharz EW et al (1998) Br J Surg 85: 1512–1516
137.
Gerullis H et al (2009) Urol Oncol (in press)
138.
Gill IS et al (2007) Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 177(4):495
139.
Gill IS et al (2007) Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 177(4):495
140.
141.
Gollob JA et al (2006) ASCO 24(Suppl 18):4538
142.
Golshayan AR et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. JCO 27(2):235–241, 2008
143.
Gontero P et al. New insights in the pathogenesis of penile shortening after radical prostatectomy: The role of postoperative sexual function. Eur Urol 6(2): 543, 2007
144.
Gore JL et al (2006) J Urol 175(4):27
145.
Gosselaar C et al (2009) How to screen for prostate cancer after 2008? The role of rectal examination. Eur Urol 8(4):286
146.
Graafland NM et al (2009) Diagnostic accuracy of FDG-PET/CT in clinically node positive penile carcinoma. Eur Urol 8(4):992
147.
Grasso M et al (2007) The role of bladder neck preservation during radical prostatectomy. Eur Urol 6(2): 129
148.
Grimison PS et al (2009) Comparison of two standard chemotherapy regimens for good prognosis germ cell tumors. JCO 27 (Suppl 15):5016
149.
Gudjonsson S et al (2008) Early intravesical epirubicin instillation after transurethral resection for non muscle invasive bladder cancer is inefficient for recurrent tumors. J Urol 179(4):1703
150.
Gudjonsson S et al (2009) Should all patients with non-muscle invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicenter study. Eur Urol 55:773–780PubMed
151.
Gulley JL et al (2005) J Urol 173 (4): 1567–1571
152.
Gupta A et al (2007) Outcomes of patients with clinical G3 bladder cancer treated with radical cystectomy. J Urol 177(4):1511
153.
Haas N et al (2009) ECOG 8802: Phase II trial of doxorubicin and gemcitabine in metastatic renal cell carcinoma with sarcomatoid features. JCO 27(Suppl 15):5038
154.
Haber GP et al (2007) Comparison between open and laparoscopic assisted radical cystectomy for bladder cancer. J Urol 177(4):1654
155.
Hahn NM et al (2006) Clin Cancer Res 12:6094–6099
156.
Hahn NM et al (2009) A multicenter phase II study of cisplatin, gemcitabine and bevacizumab as first line chemotherapy for metastatic urothelial carcinoma. JCO 27(Suppl 15):5018
157.
Haines I (2008) Docetaxel for hormone refractory prostate cancer. Lancet 372(9648):1461–1462PubMed
158.
Hainsworth JD et al (2005) J Clin Oncol 23:388
159.
Hakimi AA et al (2009) direct comparison of surgical and functional outcomes of robotic assisted vs. pure lapaoscopic radical prostatectomy: Single surgeon experience. Urology 73:119–123PubMed
160.
Harshman L, Srinivas S (2008) Continuous daily dosing of sunitinib in patients with metastatic renal cell carcinoma. Onkologie 31:432–433PubMed
161.
Hautmann RE et al (2007) Geänderte Indikationen zur Harnableitung. Dtsch Ärztebl 104(16):1092–1097
162.
Haynes AB et al (2009) A surgical safety checklist to reduce morbidity and mortality in a global population. N Eng J Med 360:491–499
163.
Heuer R et al (2009) Sequential use of the tyrosin kinase inhibitors sorafenib and sunitinib. Eur Urol 8(4):251
164.
Hinz S et al (2008) The role of PET in the evaluation of residual masses after chemotherapy for advanced stage seminoma. Eur Urol 7(3):53
165.
Holmberg et al (2003) J Urol 169(4): 179
166.
Horti J et al (2008) A randomized double blind placebo controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone refractory prostate cancer. Eur Urol 7(3):641
167.
Hu JC et al (2006) J Urol 175(4):1151
168.
169.
Hudes G et al (20067 Temsirolimus, Interferon alfa, or both for advanced renal-cell carcinoma. NEJM 356:2271–2281
170.
Hughes BE et al (2008) Lymph node metastases in intermediate risk penile cancer-a multi center experience. J Urol 179(4):506
171.
Huyghe E et al (2007) Impact on survival of diagnostic delay in testis cancer: Study on 542 patients. J Urol 177(4):583
172.
Irwin ML et al (2009) Randomized controlled trial of aerobic exercise on insulin-like growthfactors in breast cancer survivors: The Yale exercise and survivorship study. Cancer Epidemiol Biomarkers Prev 18:306–313PubMed
173.
Ismail M et al (2007) Salvage cryotherapy for recurrent prostate cancer. The UK experience. Eur Urol 6(2):705
174.
Jac J et al (2008) A phase II study with daily regimen of everolimus in patients with mRCC which has progressed on TKI therapy. J Clin Oncol 26:5113
175.
Jaffe J et al (2008) Robot assisted laüparoscopic prostatectomy: a single institution learning curve. Eur Urol 7(3):381
176.
Jakse G, Stöckle M, Lehmann J et al. (2007) Metastasiertes Harnblasenkarzinom. Deutsches Ärzteblatt 104(15):1024–1028
177.
Jeldres C et al (2007) Survival after radical prostatectomy and radiotherapy. J Urol 177(4):380
178.
Jeldres C et al (2008) Androgen deprivation therapy does not predispose to osteopenia in prostate cancer patients. Eur Urol 7(3):542
179.
Jeppesen AN et al (2009) Serum Sodium as an independent prognostic factor in metastatic renal cell carcinoma. JCO 27(Suppl 15):5102
180.
Jewett MA et al (2009) Active surveillance of small renal masses: a prospective multi-center canadian uro-oncology group trial. J Urol 181(4):896
181.
Johannsen M et al (2008) Can Tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre retrospective analysis. Eur Urol doi:10.1016/j.eururo.2008.10.021
182.
Jonasch E et al (2008) Presurgical bevacizumab in patients with metastatic clear cell carcinoma: a phase II study. J Clin Oncol 26:5104
183.
Jones JS et al (2007) Primary prostate cryoablation: Results from the cold registry. J Urol 177(4):1773
184.
Joniau S et al (2007) Radiofrequency ablation of small renal cell carcinoma: a belgian multicentre experience. Eur Urol 6(2):841
185.
Joniau S et al (2007) Radiofrequency ablation of small renal cell carcinoma: a belgian multicentre experience. Eur Urol 6(2):841
186.
Joseph JV et al (2007) Laparoscopic or robot-assisted extraperitoneal radical prostatectomy. J Urol 177(4):1589
187.
Kakiashvili D et al (2009) Post-chemotherapy retroperitoneal lymph node dissection for testicular germ cell tumours: Is surgery indicated in all and is bilateral template necessary? Eur Urol 8(4):944
188.
Kamaoi K et al (2008) Factors affecting renal function after laparoscopic partial nephrectomy. J Urol 179(4):1390
189.
Kantoff PW et al (2009) Overall survival analysis of a phase II randomized cotrolled trial of prxviral based PSA targeted immunotherapy in metastatic castration resistant prostate cancer. JCO 27(Suppl 15):5013
190.
Karellas M et al (2007) Clinical outcome following postchemotherapy RLA. J Urol 177(4):830
191.
Katz A et al (2008) Primary prostate cryoablation: updated results from 2558 patients tracked with the cold registry. J Urol 179(4):1150
192.
Kay A et al (2009) Updataed data from phase III trial of everolimus vs placebo in patients with metastatic renal cell carcinoma. Eur Urol 8(4):257
193.
Kefer JC et al (2007) Surgeon experience independently predicts biochemical recurrence following radical retropubic prostatectomy for organ confined disease. J Urol 177(4):1399
194.
Khera M et al (2009) Testosterone replacement therapy following radical prostatectomy. J Sex Med DOI:10.1111/j. 1743–6109
195.
Kleinmann N et al (2007) Is laparoscopic partial nephrectomy associated with increased morbidity? Eur Urol 6(2):850
196.
Klingler C et al (2008) HIFU of small renal tumors. J Urol 179(4):615
197.
Klotz LH et al (2006) J Urol 175(4):655
198.
Klotz LH et al (2009) Clinical results of long term follow up of a large active surveillance cohort. J Urol 181(4):1682
199.
Koie T et al (2008) Gynecologic organs sparing for female bladder cancer patients: oncological and functional outcomes. J Urol 179(4):845
200.
Kontaxis et al (2004) Eur Urol Suppl. 3(2):676
201.
Koo KC et al (2008) The significance of simultaneous transurethral resection of bladder tumor and prostate in superficial bladder tumor patients with bladder outlet obstruction. Eur Urol 7(3):436
202.
Koppie TM et al (2007) Age adjusted charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. J Urol 177(4):1512
203.
Kulkarni GS et al (2008) Waiting for radical cystectomy-impact of wait times for cystectomy on overall survival. J Urol 179(4):1550
204.
Kurteva T et al (2008) Non-clamped, non ischemic partial nephrectomy: the new gold standard. J Urol 179(4):1392
205.
Kutikov A et al (2009) MTOR pathway activation in primary renal cell carcinoma and matched metastases. J Urol 181(4), 1399
206.
Landman J et al (2007) Efficacy and complications of cryoablation for renal masses. J Urol 177(4):1299
207.
Lane BR et al (2007) Five year outcomes of laparoscopic partial nephrectomy. J Urol 177(4):496
208.
Lau CS et al (2007) Laparoscopic and robotic assisted laparoscopic cystectomy and urinary diversion. J Urol 177(4):336
209.
Laungani RG et al (2008) Robotic nephrectomy for treatment of benign and malignant disease: initial experience with report of efficacy and feasibility. J Urol 179(4):1219
210.
Lee KT et al (1998) Br J Urol 81: 705–708
211.
Leibovich BC et al. (2009) Immunohistochemical biomarkers vs clinical and pathological features in the prediction of survival for patients with metastatic renal cell cancer. J Urol 181(4):697
212.
Leijte J et al (2007) 18F-FDG positron emission tomography in penile carcinoma. J Urol 177(4):1006
213.
Leijte J et al (2007) Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol 6(2):536
214.
Leung RA et al (2008) Prostate cancer specific survival of a cohort of over 20000 men treated either conservatively or with definitive treatment. Eur Urol 7(3):389
215.
Liatsikos E et al (2007) Systematic classification of complications during endoscopic extraperitoneal radical prostatectomy. Eur Urol 6(2): 921
216.
Libertino JA et al (2008) Sutureless vesico urethral anastomosis after radical prostatectomy. Eur Urol 7(3):713
217.
Liedberg F (2009) Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: Can it make a difference? Eur Urol 8(4): 541
218.
Lin DW et al (2009) Positive fracture reduction trial Toremifen 80 mgin men on ADT demonstrates significant fracture risk in untreated placebo group. J Urol 181(4):639
219.
Lin J et al (2009) Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst 101:14–23PubMed
220.
Lippmann SM et al (2009) Effect of selenium and vitamin E on risk of prostate cancers and other cancer. JAMA 301(1):39–51
221.
Loeb S et al (2007) Complications of open radical prostatectomy in potential candidates for active monitoring. J Urol 177(4):1152
222.
Loeb S et al (2008) Long term biochemical cure rates with initial observation and delayed salvage radiotherapy after radical prostatectomy for high risk prostate cancer. J Urol 179(4):522
223.
Loeb S et al (2008) Long term biochemical cure rates with initial observation and delayed salvage radiotherapy after radical prostatectomy for high risk prostate cancer. J Urol 179(4):522
224.
Logan T et al (2008) Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor risk features. J Clin Oncol 26:5050
225.
Lopez-Coruna et al. (2002) J Urol (Suppl)
226.
Lorch A et al (2006) Single versus sequential high dose chemotherapy in patients with relapsed or refractory germ cell tumors. ASCO 24(Suppl 18):4511
227.
Lucia MS et al (2007) Finasteride and high risk prostate cancer in the prostate cancer prevention trial. J Natl Cancer Inst 99:1375–1383PubMed
228.
Machiels JP et al (2008) Prospective randomized trial comparing docetaxel, estramustine and prednisone with docetaxel and prednisone in metastatic hormone refractory prostae cancer. JCO 26:5261–5268, 2008
229.
Mao X et al (2008) Detection of TMPRSS2: ERG fusion gene in circulating prostate cancer cells. Asian J Androl 10:467–473PubMed
230.
Margulis V et al (2008) Surgical morbidity associaated with administration of targeted molecular therapies before cytoreductive nephrectomy or locally recurrent renal cell carcinoma. J Urol 180:94–98PubMed
231.
Margulis V et al (2009) Randomized trial of adjuvant Thalidomide vs observation in patients with completely resected high risk renal cell carcinoma. Urology 73:337–341PubMed
232.
Marley CS et al (2009) Negative predictive value of prostate cancer antigen 3(PCA3). J Urol 181(4):1820
233.
Martin SF et al (2003) J Urol 169 (4):173
234.
Martinez A et al (2003) J Urol 169(3):974–980
235.
Martorana G et al (2007) 11C-choline-PET/CT for preoperative N-staging in high risk prostate cancer. Eur Urol 6(2):266
236.
Mason MD et al (2007) Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double blinded placebo controlled trial: MRC PR04. J Natl Cancer Inst 99:765–776PubMed
237.
McDermott DF et al (2005) J Clin Oncol 23:133–141
238.
Meneghini A et al (2007) Bipolar transurethral resection of bladder cancer: pathomorphologic advantages. Eur Urol 6(2):603
239.
Mensink GB (1999) Nutritition in Germany. Gesundheitswesen 61:200–206
240.
Merchan JR et al (2009) Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma. JCO 27(Suppl 15):5039
241.
Messing E et al (2003) J Clin Oncol 21:1214–1222
242.
Messing E et al (2003) J Urol 169(4):396
243.
Mickisch GH et al (2000) Eur Urol 37(2):218
244.
Milecki P, Kwias Z (2006) Eur Urol Suppl 5(2):143
245.
Miller DC et al (2007) Renal health outcomes following radical or partial nephrectomy for renal cell carcinoma. J Urol 177(4):490
246.
Miller DC et al (2007) Renal health outcomes following radical or partial nephrectomy for renal cell carcinoma. J Urol 177(4):490
247.
Miller K et al (2007) Intermittent versus continuous androgen suppression in advanced prostate cancer. J Urol 177(4):1723
248.
Montella L et al (2008) Intravesical Gemcitabine versus MMC for recurrent superficial bladder tumors: a randomised prospective study. J Clin Oncol 26:5075
249.
Moon K et al (2006) Cancer 107(5):991–998
250.
Morgel et al (2009) J Urol 181(4):1699
251.
Mottet N et al (2009) Intermittent vs continuous maximal androgen blockade in metastatic prostate cancer patients. A randomized trial. Eur Urol 8(4):44
252.
253.
Motzer R et al (2006) Eur Urol Suppl 5(2):1057
254.
Motzer RJ et al (2007) Sunitinib versus Interferon alfa in metastatic renal-cell carcinoma. NEJMed 356(2):115–124
255.
Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinomas: a double –blind randomised placebo controlled phase III study. Lancet 372:449–456PubMed
256.
Motzer RJ et al (2008) RAD001 vs placebo in patients with metastatic renal cell carcinoma after progression on VEGFr-TKI therapy: results from a randomized, double bind multicenter phase III study. J Clin Oncol 26:LBA5026
257.
Moul JW et al (2008) Older men associated with advanced disease and poor outcome: An analysis of 14601 prostate cancer men in Duke prostate center. J Urol 179(4):1867
258.
Mulders P et al (2008) A multicenter, randomized phase III trial of a novel autologous therapeutic vaccine (Vitespen) versus observation as adjuvant therapy in patients at high risk recurrence after nephrectomy for renal cell carcinoma. Eur Urol 7(3):693
259.
Murat FJ et al (2007) High efficacy of salvage HIFU in treatment for radio-recurrent prostate cancer in patient with good initial prognosis. Eur Urol 6(2): 712
260.
Murat FJ et al (2007) Prostate cancer control in 463 patients treated with first generation HIFU machine. Eur Urol 6(2):711
261.
Nalluri SR et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients. JAMA 300(19):2277–2285PubMed
262.
Naumann CM et al (2007) T1G2 SCC of the penis: Surgical lymphnode staging or surveillance strategy? J Urol 177(4):1222
263.
Negrier S et al (2007) Sorafenib in patients with advanced renal cell carcinoma and prior cytokine therapy. Eur Urol 6(2):856
264.
Nicolai N et al (2009= Open versus laparoscopic retroperitoneal lymphadenectomy in clinical stage I NSGCT. JCO 27(Suppl 15):5084
265.
Nieder AM et al (2008) Prostate radiotherapy: what is the contemporary risk of bladder cancer and rectal carcinoma? J Urol 179(4):935
266.
Nilsson AE et al (2007) Learning curve concerning positive surgical margins for da vinci robotic assisted laparoscopic radical prostatectomy. J Urol 177(4):1592
267.
Ning YM et al (2008) Phase II trial of thalidomide, Bevacizumab and Docetaxel in patients with metastatic refractory prostate cancer. J Clin Oncol 26:5000
268.
Njari BB et al (2007) Comparing long term health related quality of life challenges in patients with ilealcnduit versus continent cutaneous diversion versus othotopic neobladder. J Urol 7(4):336
269.
Nobes J et al (2007) The importance of prostate brachytherapy implant technique on penile bulb dosimetry. Eur Urol 6(2):814
270.
Nogueira JL et al (2001) Eur Urol 39 (5):32
271.
Nogueira LM et al (2008) Surgical outcomes in candidate patients for active surveillance for local therapy: The inaccuracy of diagnostic template biopsy. J Urol 179(4):146
272.
Nohra J et al (2008) Sexuality after brachytherapy for localized prostate cancer: long term results. J Urol 179(4):866
273.
O‚Donnell A et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mTOR inhibitor everolimus in patients with advanced tumors. JCO 26:1588–1595
274.
275.
OkanoY et al (1998) Hinyokika Kiyo 44:381–385
276.
Olbert P et al (2008) Fast track versus conventional management in the perioperative care of radical cystectomy and urinary diversion. Results of a prospective randomized monocentric trial. J Urol 179(4):714
277.
Ong TA et al (2007) Pathological findings and survival after RLA with elevated tumor markers after chemotherapy. Eur Urol 6(2):536
278.
Osman YM (2008) Assessment of female sexual dysfunction following radical cystectomy and urinary diversion. J Urol 179(4):864
279.
Otto et al (1993) Urologe 32:189–193
280.
281.
Otto T et al (2001) J Urol 165(5):279
282.
Otto T et al (2001) Urology 57(1):55–59
283.
Otto T et al (2007) Results from the german „compassionate use program-CUP“ for Temsirolimus (TEMSR) in patients with advanced renal cell cancer (RCC) disease. Onkologie 30(Suppl):97
284.
Otto T (2007) Geänderte Indikationen zur Harnableitung. Deutsches Ärzteblatt 104 (40), 2741
285.
Otto T, Beck J, Bergmann L (2009) mTOR-Inhibition – Ein neuer Wirkmechanismus in der Onkologie. Uni-Med, Bremen
286.
Otto T (2009) Deutsches Ärzteblatt (in press)
287.
288.
Oudard S et al (2008) Safety and efficacy of Sunitinib in expanded access trial of metastatic renal cell carcinoma. Eur Urol 7(3):699
289.
Oudard S et al (2008) Sunitinib as first line treatment for metastatic renal cell carcinoma. Eur Urol 7(3):698
290.
Pabst K (1971) Klinische Gesichtspunkte zur ärztlichen Leichenschau. Z Allgemeinmed 47(25):1251–1254PubMed
291.
Palou J et al (2001) Urol 165 (5): 1488–1491
292.
Park J et al (2008) Extended lymphadenectomy durino radical cystectomy would be beneficial only in patients with clinical N0 disease and absence of palpable lymph nodes. J Urol 179(4):1601
293.
Parsons S et al (2008) Intraperitoneal treatment of malignant ascites due to epithelial tumors with Catumaxomab: A phase II/III study. J Clin Oncol 26:3000
294.
Patil S et al (2009) Prognostic factors for overall survival with sunitinib as first line therapy in patients with metastatic renal cell carcinoma. JCO 27(Suppl 15):5042
295.
Payne H et al (2009) Quality of life in a randomized placebo controlled phase III trial of the specific endothelin receptor antagonist ZD4054 in pain free or mildly symptomatic patients with metastatic hormone resistant prostate cancer. Eur Urol 8(4):50
296.
Pelz HF et al (2009) Compassionate use program Temsirolimus in patients with advanced renal cell carcinoma in germany. Eur Urol 8(4):256
297.
Pfeifer BL et al (2000) BJU Int 85:481–485
298.
Petrylak DP et al (2004) N Engl J Med 351:1513–1520
299.
Pisters LL et al (2007) Salvage cryoablation for recurrent localized prostate cancer following definitive radiation therapy. J Urol 177(4):1768
300.
Pisters LL et al (2007) Salvage cryoablation for recurrent localized prostate cancer following definitive radiation therapy. J Urol 177(4):1768
301.
Pizzocaro G et al (2007) Liver metastases following laparoscopic RLA in NSGT. J Urol 177(4):1004
302.
Pizzocaro G et al (2007) Liver metastases following laparoscopic RLA in NSGT. J Urol 177(4):1004
303.
Planas J et al (2006) Eur Urol Suppl 5(2):134
304.
Planas J et al (2006) J Urol 175(4):130
305.
Pollack A. et al (2002) Int J Radiat Oncol Biol Phys 53(5):1097–1105
306.
Porcaro AB et al (2008) Hormone refractory metastatic prostate cancer: Does PSA halving time during docetaxel treatment have a prognostic role? Eur Urol 7(3):642
307.
Poulsen AL et al (1998) J Urol 159: 629
308.
Prasad MM et al (2008) Utilization and outcomes of minimally invasive radical prostatectomy. J Urol 179(4):11
309.
310.
Procopio G et al (2009) A randomized open label prospective study comparing the association between sorafenib and IL-2 versus sorafenib alone in advanced untreated renal cell cancer. JCO 27(Suppl 15):5099
311.
Protzel C et al (2009) Expression of Annexins I, II and IV in human penile SCC. J Urol 181(4):568
312.
Puppo P et al (2007) Can we safely spare lymphadenectomy in low risk prostate cancer?Eur Urol 6(2):117
313.
Raber M et al. (2007) Comparison of holmium laser, cold knife, diatermic incision for endoscopic treatment of anastomotic stricture after radical prostatectomy. Eur Urol 6(2):290
314.
Ranniko A et al (2006)) Prostate 66:1086–1091
315.
Ravaud A et al (2006) ASCO 24 (Suppl 18):4502
316.
Ravaud A et al (2008) Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III trial. JCO 26:2285–2291
317.
Ray ME et al (2009) Potential surrogate endpoints for prostate cancer survival: Analysis of a phase III randomized trial. J Natl Cancer Inst 101:228–236PubMed
318.
Reid AH et al (2009) A multicenter phase II study of abiraterone in docetaxel pretreated castration resistant prostate cancer patients. JCO 27(Suppl 15):5047
319.
Reis LO et al (2009) Adjuvant therapy after surgery in renal cell carcinoma: systematic review with meta-analysis. J Urol 181(4):1403
320.
Resorlu B et al (2009) The role of adjuvant chemotherapy in patients with bladder cancer who had local advanced stage and/or lymph node metastasis. Eur Urol 8(4):546
321.
Richards JB et al (2008) Bone mineral density, osteoporosis, and osteoporotic fractures: a genome wide association study. Lancet 371:1505–1512PubMed
322.
Rigatti L et al (2007) Radical retropubic and laparoscopic prostatectomy: a prospective urodynamic comparison of postoperative continence. Eur Urol 6(2):975
323.
Rini BI et al (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab refractory metastatic renal cell carcinoma. JCO 26:3743–3748
324.
Rixe O et al (2007) Phase III trial of sunitinib versus interferon alfa as first line systemic therapy for patients with metastatic renal cell carcinoma. Eur Urol 6(2):860
325.
Robinson D et al (2005) Eur Urol 4(Suppl 3):103
326.
Robol MJ, Schröder FH (2009) How to screen for prostate cancer after 2008? The screening interval and the upper age cut-off screening. Eur Urol 8(4):285
327.
Roehl KA et al (2004) J Urol 171(4):1179
328.
Roehl KA et al (2008) What is the best treatment for clinically localized prostate cancer. J Urol 179(4):1441
329.
Roemeling S et al (2006) Eur Urol Suppl 5(2):727
330.
Roobol MJ et al (2009) How to screen for prostate cancer after 2008? PSA as a biopsy indicator, part II. Eur Urol 8(4):284
331.
Roque MT et al (2008) Adjuvant radiotherapy for advanced prostate cancer: Meta analyses of randomized clinical trials. J Urol 179(4):524
332.
Rosales A et al (2007) Complications of laparoscopic renal surgery. Eur Urol 6(2):846
333.
Roscigno M et al (2009) Removal of at least 8 nodes improves both staging and outcome in patients with upper tract urothelial carcinoma. Eur Urol 8(4):118
334.
Rotering J et al (2008) Single center experience in Da-Vinci prostatectomy. Eur Urol 3:379
335.
Ruggeri EM et al (2006) Cancer 106(4):783–788
336.
Ruutu M et al 820089 Resection of renal cell cancer metastases: where do we stand in 2008? Eur Urol 7(Suppl):436–442
337.
Ryan CW et al (2006) J Urol 176:972–978
338.
Ryan CW et al (2007) Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70:122–126PubMed
339.
Saad F et al (2004) Eur Urol Suppl. 3(2):615
340.
341.
Saad IR et al (2005) Long-term renal function after parital nephrectomy in patients with solitary kidney. J Urol 173:(4)
342.
Saad F et al ()2006 J Urol 175(4):1199
343.
Saad F et al (2009) CUOG phase II randomized study of custirsen combination therapy in patients with castrate resistant prostate cancer who relapsed on or within six months of 1 st line docetaxel therapy. J Urol 181(4):640
344.
Salem HK (2008) Functional and oncological outcome of genital sparing radical cystectomy in female patients with muscle invasive TCC of the bladder. J Urol 179(4):844
345.
Salonen AJ et al (2006) J Urol 175(4):1198
346.
Sartor O et al (2007) Satraplatin significantly improves progression free survival and pain control in patients with advanced hormone refractory prostate cancer. J Urol 177(4):1014
347.
Saylor PJ, Smith MR (2009) Metabolic complications of androgen deprivation therapy in prostate cancer. J Urol 181:1998–2008PubMed
348.
Scales CD et al (2008) Trends in urinary diversion following radical cystectomy in the United States. J Urol 179(4):697
349.
Schachter LR et al (2007) Early and delayed return of urinary continence after radical prostatectomy. J Urol 177(4):1605
350.
Schachter LR et al (2007) Early and delayed return of urinary continence after radical prostatectomy. J Urol 177(4):1605
351.
Schalken J et al (2008) A highly specific genetic test for prostate cancer. Prostate Cancer 1:7–8
352.
Schiavina R et al (2008) 11C-Choline PET CT for preoperative lymph node staging in prostate cancer. Eur Urol 7(3):850
353.
Schmidinger M et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. JCO 26:5204–5212
354.
Schröder FH et al (2009) How to screen for prostate cancer after 2008? Are lateral sextant biopsies obsolete? Eur Urol 8(4):384
355.
Schröder FH et al (2009) Screening and prostate cancer mortality in a randomized european study. NEJM 360(13):1320–1328PubMed
356.
Schumacher MC et al (2008) Long term follow up in patients with T1 TCC: results from a population based study. J Urol 179(4):1554
357.
Schumacher MC et al (2009) Transurethral resection of non muscle invasive bladder transitional cell cancers with or without 5 ALA under visible and fluorescent light-multicenter phase III clinical trial. J Urol 181(4):1906
358.
Schwartz RS (2009) Management of prostate cancer-polling results. NEJM 360:4
359.
Sciarra A (2008) Etoricoxib and intermitten androgen deprivation therapy in patients with biochemical progression after radical prostatectomy. J Urol 179(4):522
360.
Secin FP et al (2007) Comparative analysis of the impact of prostate volume on positive surgical margin incidence and location between open and laparoscopic radical prostatectomy. Eur Urol 6(2):749
361.
Secin FP et al (2007) Oncological outcomes of laparoscopic radical prostatectomy. Eur Urol 6(2):751
362.
Secin FP et al (2008) Learning curve of positive margin rate in laparoscopic radical prostatectomy. J Urol 179(4):12
363.
See WA et al (2004) J Urol 171(4):810
364.
Seruga B et al (2008) Intermittent androgen blockade should be regarded as standard therapy in prostae cancer. Nat Clin Pract Oncol 5:574–576PubMed
365.
Shabsigh A et al (2003) J Urol 169 (4):264
366.
Shah KK et al (2007) Robot assisted radical prostatectomy: Histopathologic data of 1200 cases. Eur Urol 6(2):412
367.
Shah KK et al (2007) Radiofrequency ablation of renal tumors. J Urol 177(4):1303
368.
Shahani S et al (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93:2042–2049PubMed
369.
Shappell SB et al (2009) PCA3 urine mRNA testing for prostate carcinoma. Urology 73:363–368PubMed
370.
Sharma P et al (2006) ASCO 24(18 Suppl):4544
371.
Sharp DS et al (2009) Clinical outcome and predictors of survival in late relaps of germ cell tumours. JCO 26:5524–5529
372.
Shayegan B et al (2005) Clinical outcome of intermediate- and poor-risk patients with non-seminomatous germ cell testicular cancer (NSGCT) following post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND). J Urol 173
373.
374.
Shepard DR et al (2008) A multicenter prospective trial of sorafenib in patients with mRCC refractory to prior sunitinib or bevacizumab. J Clin Oncol 26:5123
375.
Shinohara N et al (2006) Eur Urol Suppl 5(2):1076
376.
Siddiqui SA et al (2008) The impact of adjuvant therapy after radical prostatectomy for patients with pathological pT3b prostate cancer. J Urol 179(4):722
377.
Silberstein J et al (2009) Penile carcinoma: results from the california cancer registry. J Urol 181(4):915
378.
Silberstein J et al (2009) Urine assays for PCA3 and TMPRSS2: ERG gene fusion to predict the diagnosis of prostate cancer. J Urol 181(4):2244
379.
Simone G (2009) Laparoscopic versus open nephroureterectomy: Results of a prospective randomized study. Eur Urol 8(4):122
380.
Sirintrapun SJ et al (2003) J Urol 169(4):232
381.
Smith MR et al (2007) Predictors of skeletal complications in men with hormone refractory metastatic prostate cancer. Urology 70:315–319PubMed
382.
Smith MR et al (2007) Phase III interim analysis demonstrates toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 177(4):1015
383.
Smith Y et al (2007) The feasibility of a study of adjuvant therapies in node positive penile cancer. Eur Urol 6(2):1048
384.
Smith MR et al (2009) A randomized double blind, placebo controlled trial of denusomab in men receiving androgen deprivation therapy for non metastatic prostate cancer. Eur Urol 8(4):846
385.
Smith MR et al (2009) Effects ot twice-yearly sc. Denusomab on bone mineral density in men receiving androgen deprivation therapy for non metastaic prostate cancer. J Urol 181(4):638
386.
Snyder PJ et al (1999) J Clin Endocrinol Metabol 84:2647–2653
387.
Sofikerim M et al (2008) What‚s the role of percutaneous needle core biopsy in diagnosis of renal masses? J Urol 179(4):1205
388.
Soga N et al (2008) Percutaneous RFA for pulmonary metastases associated with renal cell carcinoma: optimal treatment option. J Urol 179(4):473
389.
Sokoloff MH et al (2008) Management of recurrent prostate cancer after radiotherapy. J Urol 179(4):1884
390.
Soloway MS et al (2002) Urololgy 167 (1):112–116
391.
Somani BK et al (2008) Changing paradigms in urinary diversion and bladder replacement surgery: evidence from a systematic review. J Urol 179(4):698
392.
Sooriakumaran P et al (2005) Urology Supplement. 4(3):44
393.
Sosman JA (2008) Improving outcomee in patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 8(3):481–490PubMed
394.
Souza PL et al (2008) Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon. J Clin Oncol 26:5116
395.
Spigel DR et al (2005) J Clin Oncol 23:387
396.
Srinivasan R et al (2009) A phase II study of two dosing regimens of GSK 1363089, a dual MET/VEGFR2 inhibitor in patients with papillary renal cell carcinoma. JCO 27(Suppl 15):5103
397.
Stadler WM et al (2009) Randomized trial of p53 targeted adjuvant therapy for patients with organ confined node negative urothelial bladder cancer. JCO 27(Suppl 15):5017
398.
Staehler M et al (2008) Metastasectomy significantly prolongs survival in patients with mRCC: 10 years experience in 240 patients. J Clin Oncol 26
399.
Stein JP et al (1998) J Urol 159: 823
400.
Steiner H et al (2007) High rate of retroperitoneal teratoma despite complete remission after chemotherapy for metastatic non seminomatous germ cell tumor. Eur Urol 6(2):537
401.
Sterbis JR et al (2007) Integrated PET/CT: A novel imaging modality in testis cancer. J Urol 177(4):1005
402.
Sternberg C et al (2007) Satraplatin significantly improves progression free survival and pain control in patients with advanced hormone refractory prostate cancer. J Urol 177(4):1014
403.
Sternberg C et al (2008) Sartraplatin increases progression free survival and delays pain progression in patients with hormone refractory prostate cancer that have progressed after prior Docetaxel. Eur Urol 7(3):638
404.
Sternberg CN et al (2009) A randomized double blind phase III study of pazopanib in treatment naive and cytokine pretreated patients with advanced renal cell carcinoma. JCO 27(Suppl 15):5021
405.
Steuber TP et al (2008) (18) Fluorcholine combined in – line- PET-CT-scan for detection of lymph node metastasis prior to radical prostatectomy: results from a prospective histology based study. J Urol 179(4):138
406.
Stöckle M, Lehmann J, Krege S et al. (2007) Therapie und Prognose des lymphogen metastasierten Harnblasenkarzinoms Deutsches Ärzteblatt 104(14):959–963
407.
Stöckle M, Siemer S (2008) Robotisch unterstützte DaVinci-Laparoskopie. Beginn eines neuen Zeitalters in der operativen Urologie? Urologe 47(4):409–413PubMed
408.
409.
Storm DW et al (2007) Robotic assisted laparoscopic nephrectomy. Experience with 100 cases. J Urol 177(4):697
410.
411.
Studer U et al (2006) J Urol 175(4):1592
412.
Studer U et al (2007) Which subgroup of patients with newly diagnosed prostate cancer not suitable for local treatment with curative intent are at risk to die from prostate cancer and benefit from immediate androgen deprivation?Eur Urol 6(2):19
413.
Suardi N et al (2008) Currently used criteria for active surveillance in men with low risk prostate cancer. An analysis of pathological features. J Urol 179(4):429
414.
Suardi N et al (2008) External-beam radiation therapy increases the rate of secondary malignancies relative to radical prostatectomy in men with prostate cancer. Eur Urol (3):187
415.
Suarez Novo JF et al (2009) Impact on health related quality of life of retropubic radical prostatectomy, external beam radiation and brachytherapy as treatment of prostate cancer: Results at 3 years follow up of a prospective, longitudinal and multi-institutional study. Eur Urol 8(4):750
416.
417.
Sylvester R et al (2004) Eur Urol 3(Suppl 2):478
418.
Szczylik C et al (2009) Overall survival with sunitinib vs IFN alfa as first line treatment for metastatic renal cell carcinoma. Eur Urol 8(4):246
419.
Tabernero J et al (2008) Dose- and schedule dependent inhibition of the mTOR pathway with everolimus: a phase I tumor pharmacodynamic study in patients with solid tumors. JCO 26:1603–1610
420.
Takahashi T et al (2005) J Urol 173(4)
421.
Tanaka C et al (2008) Identifying optimal biological doses of everolimus in cancer patients based on modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. JCO 26:1596–1602
422.
Tannir NM et al (2004) ASCO Annual Meeting Proceedings. J Clin Oncol 22(14):4607
423.
Tannir NM et al (2006) Cancer 107:2254–2261
424.
Tannir NM et al (2008) A randomized phase II trial of sorafenib versus sorafenib versus low dose interferon. J Clin Oncol 26:5093
425.
Tannir NM et al (2009) Phase II trial of ABT-869 in advanced renal cell cancer after sunitinib failure. JCO 27(Suppl 15):5036
426.
Tannock IF et al (2004) N Engl J Med 351:1502–1512
427.
Thalmann GN et al (2009) Radical cystectomy with extended lymph node dissection in over 1000 patients: Good survival and low recurrence rates. Eur Urol 8(4):535
428.
Theodorescu D et al (2006) Lancet Oncol 7:230–240
429.
Thibault F et al (2008) Perioperative use and surgical complications of sunitinib in metastatic renal cell carcinoma. J Urol 179(4):481
430.
Thompson IM et al (2003) NEJM 349:215–224
431.
Thompson IM et al (2005) J Urol 173(4)
432.
Thompson IM et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long term follow up of a randomized clinical trial. J Urol 181:956–962PubMed
433.
Thüroff S, Chaussy C (2006) Eur Urol Suppl 5(2):1036
434.
Thüroff JW et al (1998) World J Urol 16: 235–241
435.
Thyavihally YB et al (2007) Simultaneous inguinal lymph node dissection in patients with carcinoma of the penis. J Urol 177(4):1007
436.
Thyavihally YB (2008) PET in the evaluation of post-chemotherapy residual masses in patients with metastatic testicular tumors: a prospective study. J Urol 179(4):772
437.
Thyavihally YB et al (2009) The role of PET scan in detecting inguinal nodal metastases in carcinoma penis: a prospective study. J Urol 181(4):565
438.
Tillack A (2009) Zweittumor bei primärer Krebserkrankung. Forum 24:28–31
439.
Tombal B et al (2006) J Urol 175(4):1599
440.
Tombal B et al (2009) Degarelix vs leuprolide treatment in patients with advanced prostate cancer: PSA failures during a randomised phase III trial. Eur Urol 8(4):38
441.
Touijer K et al (2007) Radical prostatectomy: a non randomized comparative analysis of outcomes between the open and laparoscopic approach. Eur Urol 6(2):750
442.
Trojan L et al (2007) Complications and side effects of LDR brachytherapy for the treatment of prostate cancer. Eur Urol 6(2):818
443.
Tsuzuki T et al (2005) J Urol 173(2):450–453
444.
Tunn UW et al (2007) Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy. J Urol 177(4):600
445.
Uemura H (2009) Pressekonferenz, EAU/Japanese Meeting Stockholm 20.4
446.
Van der Aa MNM et al (2009) Cystoscopy revisited as the gold standard for detection of bladder cancer recurrences: diagnostic review bias in a prospective trial. Eur Urol 8(4):1016
447.
Van der Veldt AAM et al (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99:259–265
448.
van Gringer et al (2009) J Urol 181(4):1699
449.
Van Poppel et al (2006) Eur Urol Suppl 5(2):630
450.
Verhoest G et al (2009) Plasma and serum VEGF as prognostic factor in renal cancer: a prospective analysis in 367 patients. J Urol 181(4):594
451.
Verze P et al (2009) Phase I-II study with intravenous paclitaxel and oral cyclophospamide in patients with metastatic carcinoma of the bladder. Eur Urol 8(4):544
452.
Vickers AJ et al (2007) Effects of patient risk on the learning curve for radical prostatectomy. J Urol 177(4):1398
453.
Vis A et al (2007) Overall survival in the intervention arm of a randomised controlled screening trial for prostate cancer compared to a clinically diagnosed cohort. Eur Urol 6(2):607
454.
Vogelzang NJ (2006) J Clin Oncol 24(1):1–6
455.
Vogelzang NJ et al (2009) Phase II study of perfosine in metastatic renal cell cancer progressing after prior therapy with a VEGF receptor inhibitor. JCO 27(Suppl 15):5034
456.
Volkmer BG et al (2005) BJU Int 95(7):972–976
457.
von der Maase H (2001) Semin Oncol 28:1–3
458.
von der Maase H et al (2005) J Clin Oncol 23: 4602–4608
459.
Walsh PC et al (2007) Localized prostate cancer. N Engl J Med 357:2696–2705PubMed
460.
Wang JG et al (2007) Robotic versus open radical cystectomy. J Urol 177(4):337
461.
Wang Y et al (2007) Polymorphism in DNA repair genes, cigarrete smoking and the risk of urothelial cancer. J Urol 177(4):234
462.
Wang GJ et al (2009) Prospective comparison of perioperative and pathologic outcomes between robotic and open radical cystectomy. J Urol 181(4):1679
463.
Westermann D et al (2007) Long term follow up results after one cycle BEP in patients with high risk stage I NSGT. Eur Urol 6(2):535
464.
Wheeler E et al (2002) J Urol (Suppl)
465.
Whorf RC et al (2008) Phase II study of bevacizumab and everolimus in the treatment of advanced RCC. J Clin Oncol 26:5008
466.
Widmark A et al (2009) Endocrine treatment with or without radiotherapy, in locally advanced prostate cancer: an open randomised phase III trial. Lancet 373:301–308PubMed
467.
Wiegel T (2005) ASCO Annual Meeting. J Clin Oncol
468.
Wirth M et al (2006) Eur Urol Suppl 5(2):913
469.
Wirth M et al (2005) Prostate Cancer Prostatic Dis 8(2):194–200
470.
Witjes JA et al (2007) Intravesical hyperthermia and mitomycin c for carcinoma in situ of the urinary bladder. Eur Urol 6(2): 150
471.
Witte et al (2009) Clin Cancer Res (in press)
472.
Witzsch U et al (2007) Cryoablation of prostate cancer using 17 gauge cryoneedles technology. Eur Urol 6(2):713
473.
Wood CG et al (2007) A multicenter, randomized phase III trial of a novel autologous therapeutic vaccine versus observation as adjuvant therapy in patients at high risk recurrence after nephrectomy for renal cell carcinoma. J Urol 177(4):633
474.
Wood CG et al (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre open-lable, randomised phase III trial. Lancet 372:145–154PubMed
475.
Yanaihara H et al (2008) Influence of hospital and surgeon volume on operative time, blood loss and perioperative complications in radical nephrectomy. Eur Urol 7(3):845
476.
Yang JC et al (2003) NEJM 349:427–434
477.
Yang JC (2004) Bevacizumab for patients with metastic renal cell cancer. Clin Cancer Res 10:6367–6370
478.
Zhao LC et al (2007) Laparoscopic partial nephrectomy versus cryoablation for exophytic renal tumors. J Urol 177(4):1303
479.
Zheng SL et al (2008) N Engl J Med 358:910–919
480.
Zini L et al (2009) Population based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 73:342–346PubMed
481.
Winquist E, Lukka H (2004) J Urol 171:561–569
482.
Cella et al (2008) JCO 26:3763–3769
483.
Gerullis et al (2009) Cancer Chemother Pharmacol 63:1097–1102
484.
485.
Schröder FH et al (2005) Early versus delayed endocrine treatment of pN1–3 M0 prostate cancer without local treatment of the primary tumor: results of the European Organisation for the Research and Treatment of Cancer Genito-urinary Group. J Urol 172 (3):923–927
486.
Stöckle M et al (2009) Dtsch Ärztebl 106(8):117–122
487.
Kirsh VA (2006) J Natl Cancer Inst 98(4):245–254
488.
Chinnaiyan A et al (2009) Nature 457:910
489.
Conort P et al (2007) Treatment of localized prostate cancer by high intensity focused ultrasound; results of the first french prospektive trial on patients not previousloy tretaed: minimum of five years follow up. J Urol 179(4): 1452
490.
Patchell T et al (2005) Lancet 366:643
491.
Bracarda S et al (2008) Sorafenib pulus interferon in metastatic renal cell carcinoma. Eur Urol 7(3):696
492.
Kiemeney LA et al (2008) Nature Genetics 40(11):1307–1312
493.
Nomata K et al (2001) Urol 165(5):191
494.
Sherif H et al (2004) Eur Urol Suppl 3(2):687
495.
Skinner DG et al (1991) J Urol 145:459–464
496.
Stephenson AJ et al (2005) 2 cycles cisplatin-based chemotherapy for low volume long term results. J Urol 173(4)
497.
Dotan ZA et al (2005) Postchemotherapy retroperitoneal lymph node dissection for patients with elevated tumor serum markers. J Urol 173(4):429
498.
Krege S et al (2004) J Urol 171(4):922
499.
Warde P et al (2005) Outcome in stage I seminoma managed by radioation therypy and surveillance. J Urol 173(4)
500.
Pinkawa M, Eble MJ (2009) Onkologie 2:29–34
Metadaten
Titel
Uro-Onkologie – Update 2009
verfasst von
Prof. Dr. T. Otto
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Die Urologie / Ausgabe 9/2009
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-009-2083-4

Weitere Artikel der Ausgabe 9/2009

Der Urologe 9/2009 Zur Ausgabe

Leitthema

Die Patientenaufklärung zur Prostatakarzinomfrüherkennung ist unzureichend*

URO-Telegramm

URO-Telegramm Heft 9/2009

Leitthema

Der spät diagnostizierte Hodenhochstand*

Österreichischer Berufsverband

Mitteilungen des Berufsverbands der Österreichischen Urologen e.V. (bvU)

Originalien

Docetaxel-refraktäre Patienten mit metastasiertem hormonrefraktären Prostatakarzinom

Originalien

Adjuvante autologe Tumorvakzine beim Nierenzellkarzinom

Neu im Fachgebiet Urologie

10.04.2024 | PSA-Screening | Nachrichten

Einladung zum PSA-Screening senkt die Krebssterblichkeit

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet

05.04.2024 | Benigne Prostatahyperplasie | Nachrichten

TURP hat Vorteile im Vergleich mit der Embolisation

04.04.2024 | Erektile Dysfunktion | Nachrichten

Langes Sitzen in der Freizeit korreliert mit erektiler Dysfunktion
weitere anzeigen

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen